Table 4.

Changes in quality of life [QoL] of Crohn’s disease [CD] patients as measured by the Inflammatory Bowel Disease Questionnaire [IBD-Q] before [T0] and after riboflavin supplementation [T3].

Total study population	T0	T3	p-value
Total score IBD-Q	173 [152; 193]	177 [160; 196]	0.001
Bowel symptoms	55 [48; 61]	58 [49; 64]	0.002
Systemic symptoms	22 [19; 27]	24 [19; 29]	<0.001
Emotional function	67 [60; 73]	66 [60; 74]	0.257
Social function	32 [26; 35]	32 [26; 34]	0.631
FC <200 µg/g	T0	T3	p-value
Total score IBD-Q	175 [157; 200]	178 [162; 205]	0.001
Bowel symptoms	56 [48; 63]	59 [51; 66]	0.005
Systemic symptoms	22 [19; 27]	24 [19; 30]	<0.001
Emotional function	68 [61; 73]	67 [61; 82]	0.059
Social function	32 [27; 35]	33 [27; 35]	0.195
FC >200 µg/g	T0	T3	p-value
Total score IBD-Q	171 [145; 188]	177 [143; 187]	0.253
Bowel symptoms	53 [47; 60]	57 [48; 61]	0.163
Systemic symptoms	22 [19; 28]	24 [18; 28]	0.127
Emotional function	63 [57; 70]	64 [57; 71]	0.714
Social function	30 [26; 33]	29 [23; 34]	0.361

Response scores are presented as median [interquartile range] with corresponding p-values according to paired Wilcoxon’s signed-rank test. Two-sided p-values <0.05 are considered statistically significant. Significances are indicated in bold.

FC, faecal calprotectin.